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Abstract 
To study the function and structure of membrane proteins high quantities of pure and 
stable protein are needed. One of the first hurdles in accomplishing this is 
expression of the membrane protein at high levels and in a functional state. 
Membrane proteins are naturally expressed at low levels so finding a suitable host 
for over expression is imperative. Multidrug resistance protein 4 (MRP4) or ATP-
binding cassette subfamily C member 4 (ABCC4) is a multi-transmembrane protein 
which is able to transport a range of organic anionic compounds (both endogenous 
and xenobiotic) out of the cell. This versatile transporter has been linked with 
extracellular signalling pathways and cellular protection, along with conferring drug 
resistance in cancers. Here we report the use of MRP4 as a case study to be 
expressed in three different expression systems: mammalian, insect and yeast cells 
to gain the highest yield possible. Interestingly, using the baculovirus expression 
system with Sf9 insect cells produced the highest protein yields. Vesicular transport 
assays were used to confirm MRP4 expressed in Sf9 was functional using a 
fluorescent cAMP analogue (fluo-cAMP) instead of the traditional radiolabelled 
substrates. MRP4 transported fluo-cAMP in an ATP dependent manner. Specificity 
of functional expression of MRP4 was validated by the use of non-hydrolysable ATP 
analogues and MRP4 inhibitor MK571. Functionally expressed MRP4 in Sf9 cells 
can now be used in downstream processes such as solubilisation and purification in 
order to better understand its function and structure.  
Introduction 
One of the limitations of membrane protein structural biology is expressing the 
membrane protein of interest. The challenge lies not only in expressing the protein of 
interest but also expressing it to a high level in its native conformation(s). Most 
membrane proteins are naturally expressed in low levels, and so obtaining sufficient 
amounts of the native membrane proteins to conduct functional and structural 
studies requires large amounts of resources and is really only realistic for proteins 
which are naturally abundant in certain cell types such as rhodopsin in the retina1.   
To overcome the problem of low natural expression, recombinant overexpression 
can be performed, increasing the yield per cell2. Another advantage of recombinant 
expression is the ability to easily add tags to enable efficient separation of the target 
protein from the other membrane proteins. Common purification tags include 
histidine, strep and flag tags which can increase the purity and yield though affinity 
purification3. However, it is important these tags do not interfere with the function of 
the protein. Recombinant membrane protein expression is also a means of 
producing more stable membrane proteins through the use of mutagenesis and 
protein engineering but the native conformation will be altered and therefore the 
correct function and structure will not be discovered4. 
Effective recombinant membrane protein expression requires finding a suitable host. 
If the membrane protein is a prokaryotic protein then E. coli could potentially be 
used. The advantages of using E. coli for recombinant overexpression of membrane 
proteins is that it can be carried out quickly as they have a high growth rate, high 
quantities of cells are easily achieved and are cost effective5. If the target protein is 
eukaryotic, such as human membrane proteins, a eukaryotic host such as yeast, 
insect or mammalian cells can be used.  
Insect cell expression is a commonly used expression system for recombinant 
mammalian membrane proteins. It requires the production of a recombinant 
baculovirus carrying the gene of interest, and infection of insect cells, such as 
Spodoptera frugiperda (Sf9), with this virus leads to protein expression6. Inclusion 
bodies are rarely formed with the baculovirus expression system in insect cells unlike 
in E.coli7. This system has also been beneficial in the production of multiprotein 
subunit complexes8-10.  
Two main strains of yeast have been used for membrane protein expression, Pichia 
pastoris and Sacchromyces cerevisiae. Pichia pastoris requires the integration of the 
recombinant gene of interest into the yeast genome allowing a stable strain to be 
produced but it is not possible to control the number of copies or location of the 
recombinant gene. Whereas Sacchromyces cerevisiae expression tends to use 
plasmids containing the gene of interest, similarly to E. coli. However the advantages 
of using Pichia pastoris are the high cells densities it can grow to with exceptionally 
high yields of correctly folded protein meaning large amount of recombinant protein 
can be produced11, which is why Pichia pastoris was chosen for this study. 
Mammalian cell expression offers potentially the most relevant cellular environment 
for human membrane proteins. Two of the most common mammalian cell lines used 
are human embryonic kidney (HEK) and Chinese hamster ovary (CHO) cells6, 12. The 
HEK cell line was chosen for this study as it has increasingly been used for 
membrane protein expression13. Proteins expressed in HEK cells are usually fully 
glycosylated compared to Sf9 cells8. HEK cells can be made to overexpress 
recombinant membrane proteins by either producing a transient or stable cell lines14. 
Whilst transient expression can give considerable batch-to-batch variability, creating 
stable cells often reduces the expression yield. Thus transient transfections were 
utilised in this study.  
ATP Binding Cassette (ABC) transporters are integral membrane proteins that are 
found in all types of organisms from prokaryotes to humans. They utilise energy from 
ATP binding and hydrolysis to transport a variety of substrates across the biological 
lipid bilayer15. In humans, the 48 different ABC transporters can be separated into 
seven different subfamilies ABCA- ABCG of which Multidrug Resistance Protein 4 
(MRP4/ABCC4) is part of the C subfamily16.  
MRP4 can be found in a wide range of cells all over the human body including blood 
cells, neurons, testis, ovaries, adrenal glands, prostate tubuloacinar cells and renal 
proximal tubule cells17.  Endogenously MRP4 is able to transport substrates which 
are involved in inflammation, such as prostaglandins and leukotrienes18 and cell 
signalling, including cyclic nucleotides such as cyclic AMP (cAMP) and cyclic GMP 
(cGMP)19. It has also been shown to transport a wide range of drugs and their 
metabolites including anticancer, antiviral and antibiotic molecules20. 
How MRP4 is able to transport such a wide variety of substrates is not well known. In 
particular how it can recognise, bind and transport both relatively hydrophilic 
molecules like cAMP and hydrophobic molecules such as bile salts or drugs like 
methotrexate is unclear. This could be due to the lack of structural knowledge about 
the transmembrane domains (TMD) of MRP4, which are responsible for transporting 
substrates. Therefore functional and structural studies will help reveal the intricacies 
of this membrane protein. 
A 
In this study we investigated the functional overexpression of MRP4 by examining 
which approach gave the best expression yield and then characterized the function 
with a fluorescent vesicular transport assay. 
  
Materials and Methods 
Sf9 expression 
Expression of the recombinant human MRP4-his6 within Sf9 cells was conducted 
using a baculovirus encoding for recombinant MRP4 generated from a pFastBac-
MRP4-his6 construct as described previously21. Cells were grown in shaker cultures 
using Insect Xpress media (Lonza). To find the optimal expression conditions cells at 
a density of either 1 or 2 million per ml were infected with baculovirus using a 
multiplicity of infection (MOI) of either 2 or 4, and cells harvested after 24, 48 or 72 
hours.  
Pichia Pastoris expression 
Growth media: BMGY (Buffered Glycerol-complex Medium) and BMMY (Buffered 
Methanol-complex Medium) was made using 10 g of yeast extract and 20 g peptone 
was dissolved in 700 mL water and autoclaved. To which: 100 mL 1 M potassium 
phosphate buffer, pH 6.0, (13.2 mL of 1M K2HPO4 and 86.8 mL of 1M K2HPO4), 100 
mL 10X YNB (13.4% Yeast Nitrogen Base with Ammonium Sulphate without amino 
acids), 2 mL 0.02% Biotin, 100 mL 10% Glycerol for BMGY or 100 mL 5% Methanol 
for BMMY was added after filter sterilisation. 
The recombinant pPICZαC-MRP4-his6 construct was created using a double digest 
of the pFastBac MRP4-his6 plasmid and pPICZαC with EcoRI, followed by ligation of 
MRP4-his6 into the pPICZαC plasmid, at a plasmid to insert molar ratio of 1:3, 
overnight at 16oC. pPICZαC MRP4-his6 was linearized using PmeI and transformed 
into P. pastoris X33 using electroporation. Colonies containing integrated MRP4 
were grown essentially as described previously for Pichia expression of a membrane 
protein22.  Briefly, colonies were grown in 25 mL BMGY in sterile 250 mL flasks at 
30°C in a shaking incubator (250-300 rpm) until the culture reached an OD600 of 2-6. 
Cells were harvested by centrifugation at 3000 g for 5 minutes, all BMGY removed, 
then washed with BMMY and resuspended in BMMY at an OD600 of 1.0 before being 
returned to the shaking incubator at 22 or 30°C. Sterilized pure methanol was added 
every 24 hours to a final concentration of 0.5% (v/v) methanol. Samples were taken 
every 24 hours over a 72h period. 
HEK293T expression 
pcDNA3.1-MRP4-his6 plasmid was constructed by restriction digestion of MRP4-his6 
out of the pFastBac plasmid and ligation into a pcDNA 3.1 Zeo + plasmid. pOPINE-
MRP4–3C-flag-his8 was made by the OPPF (Oxford Protein Production Facility). 
pcDNA3.1-MRP4 without a his-tag was a kind gift from Professor Susan Cole 
(Queens’ University, Kingston). HEK293T cells were seeded in a 6 well plate with 
300,000 cells/well in DMEM containing 10% FBS and 1% penicillin/streptomycin 24 
hours prior to transfection. 3 hours prior to transfection the media was replaced with 
low serum DMEM containing 2.5% FBS and 1% penicillin/streptomycin. For 
transfection, 4µg of plasmid DNA was combined with 18µL of 10mM linear 
polyethylenimine (PEI, Polysciences) and 100µL reduced serum media (OPTIMEM) 
and added to each well. 24 hours after transfection the media was replaced with 
DMEM containing 10% FBS 1% penicillin/streptomycin. Samples were taken every 
24 hours over a 72 hour period.  
Cell lysis and membrane preparation 
For both Sf9 and HEK293T, cells were harvested by centrifugation (5000g for 10 
minutes) and cell pellets were resuspended in buffer 1 (50mM Tris-HCl pH 7.4, 
250mM Sucrose, 0.25mM CaCl2) containing protease inhibitors (1.3µM benzamidine, 
1.8µM leupeptin and 1µM pepstatin). Cells were disrupted through nitrogen 
cavitation at 500 psi for 15 minutes, 4°C. The cell lysate was centrifuged at 750g for 
10 minutes to remove cell debris; the supernatant was then ultracentrifuged at 
100,000 g for 20 minutes, 4°C. The membrane pellet was resuspended in buffer 2 
(50mM Tris-HCl pH 7.4, 250mM Sucrose) and stored at -80oC. 
P. pastoris cells were pelleted via centrifugation at 2500g for 30 minutes and then 
resuspened in buffer 3 (5.5 % w/v glycerol, 2 mm EDTA, 100 mM NaCl, 50 mM 
NaH2PO4, 50 mM Na2HPO4) containing EDTA free protease inhibitor tablets 
(Roche). Cells were resuspened at a buffer (mL) to cell pellet weight (g) ratio of 
3:1.Resuspended cell pellets were homogenised by passing them through the 
Emulsi Flex C3 machine (Avestin) three times. The homogenized cells were 
centrifuged at 5000g for 5 minutes, the supernatant was then centrifuged at 13,000g 
for 15 minutes and finally the supernatant was centrifuged for 1 hour at 100,000g. 
Membrane pellets were resuspended in buffer 4 (20 mM HEPES pH 8, 50 mM NaCl, 
10 % w/v glycerol) containing protease inhibitor (Roche) and stored at -80oC. 
Analysis of expression 
Expression of MRP4 was monitored by Western blot. Total protein concentration of 
membranes was measured using a BCA assay kit (Pierce). Specified amounts (µg) 
of total protein were loaded on 8% SDS-PAGE, transferred to PVDF membrane and 
blocked with 5% (w/v) BSA in TBS-T (20mM Tris pH 7.5, 150mM NaCl, 0.01% (v/v) 
Tween-20). Blots were probed either with a mouse anti-his antibody (R & D 
Systems) at a dilution of 1:500 or a rat anti-MRP4 antibody (M4I-10, Enzo) at 1:100, 
followed by anti-mouse HRP (Cell Signalling, 1:3000) or anti-rat HRP (sigma, 
1:3000). All were visualised using chemiluminescence (Pierce) and a C-Digit 
Western Blot scanner (Licor). 
Vesicular Transport Assays (VTAs) 
VTAs were based upon the study by Reichel et al 23, and performed using Sf9 
control and Sf9 MRP4 expressing cell membrane vesicles from the optimised 
expression conditions (1x106 cells/ml, MOI of 2, 48 hour incubation). 10 – 100 μg of 
total protein membrane protein were incubated with 10mM ATP (plus an ATP 
regenerating system: 100μg/mL creatine kinase and 10mM creatine phosphate) or 
AMP and 10mM MgCl2 and 1 -100μM 8- (2-[Fluoresceinyl]aminoethylthio) 
adenosine- 3', 5'- cyclic monophosphate (fluo-cAMP) (Biolog). VTA were conducted 
in buffer 2 in a 50μL volume and incubated at room temperature for 10 minutes. This 
time period was chosen since previous kinetic studies showed it to be within the 
linear range23. For vanadate inhibition, 500μM sodium orthovanadate was added 
along with ATP. AMP-PNP inhibition was conducted by replacing the ATP with 
10mM AMP-PNP. 0.01 – 10uM MK571 was added along with ATP to measure 
MK571 inhibition.  
After incubation transport was stopped by the addition of 950μL of ice cold buffer 2. 
Samples were either filtered using a PVDF filter (Millipore 0.45μM) or centrifuged at 
14,000 g for 5 minutes. The filter was washed with 5mL of ice cold buffer 2 or the 
pelleted vesicles washed with 1 mL ice cold buffer 2. The filter or pellet was 
solubilised with 1mL of SDS/HEPES buffer (1% (w/v) SDS and 7.5mM HEPES) for 
15 minutes. The amount of fluo-cAMP transported was measured by the 
fluorescence signal (RFU) of the solubilised sample measured on a Perkin Elmer 
LS55 Fluorescence Spectrometer (excitation 480 ± 5nm, emissions 500-600 
±20nm). Samples were run in triplicate and an average of 5 scans was taken for 
each sample.   
Data fitting for concentration curves in the VTA was performed by fitting a Michaelis-
Menten and for MK571 inhibition used a dose-response curve. Statistical analysis 
was performed using an un-paired two-tailed t-test or one-way ANOVA. Data fitting 
and statistical analysis was carried out using GraphPad prism. 
  
Results 
MRP4 Expression 
The first step of the investigation was to determine the optimal conditions for MRP4 
expression in each of the three expression systems, Sf9 insect cells, P. Pastoris 
yeast cells and HEK293T mammalian cells. For Sf9 insect cell expression the cell 
density, multiplicity of infection and infection period were altered. Western blots in 
Figure 1A show the expression of MRP4 within Sf9 cells was successful.  As 
reported previously MRP4 expressed in Sf9 cells migrated at approximately 
150kDa24. After 48 hours an increased expression was seen compared to 24 hours 
(Supplementary Figure 1A), however after 72 hours the expression level decreased 
again, possibly due to viral lysis of the cells. Increasing the cell density from 1x106/ml 
to 2x106/ml did not significantly improve the expression yield, and changing the MOI 
had little effect.  It should be noted that a lower molecular weight band is also visible 
in several lanes, particularly those showing higher levels of expression, however this 
band is not specific to these highly expressing conditions and is visible in all samples 
if the exposure time is increased, and has been observed previously when MRP4 
was expressed in Sf9 cells24.  Therefore the optimal expression conditions in Sf9 
cells were 48 hours with 1-2 x 106 insect cells/mL at either an MOI of 2 or 4. 
After successful integration of MRP4 into P. pastoris the temperature and time were 
altered to gain the highest yield possible in shaker flasks. Figure 1B shows the 
expression of MRP4 within P. pastoris. Notably the MRP4 from P. pastoris runs at a 
higher molecular weight than the Sf9 expressed MRP4.  At a lower temperature 
(22oC) the highest expression level was achieved after 24 hours and then decreased 
over the 72 hour period. At higher temperature (30oC) the expression level increased 
over time reaching the highest expression level after 72 hours. The use of a 2L 
bioreactor for P. pastoris expression was also investigated (Supplementary Figure 
1B), however this gave a lower yield of MRP4 expression than the shaker flasks. The 
optimal conditions for P. pastoris expression were therefore obtained using shaker 
flasks at 30°C for 24 hours. However it should be noted that this still gave a lower 
level of expression than the Sf9 cells. 
Transient transfections were performed in HEK293T cells using PEI as a transfection 
reagent.  As shown in Figure 1C, in contrast to Sf9 and P. pastoris, HEK293T cells 
express MRP4 endogenously. Transfection of the HEK293T cells with pcDNA3.1-
MRP4his gave only marginally increased levels of MRP4 expression. Similarly 
transfection with pOPINE-MRP4-3C-flag-his8 led to very little overexpression of 
MRP4 (Supplementary Figure 1C). In contrast transfection with pcDNA-MRP4 
without a his-tag gave a substantial time-dependent overexpression of MRP4 
(Supplementary Figure 1C). 
MRP4 was successfully overexpressed in all three expression systems.  However in 
HEK293T cells it was only achieved in the absence of a his-tag, which would make 
downstream purification challenging. The yield obtained with Sf9 cells was higher 
than that achieved with P. pastoris. In addition the MRP4 from Sf9 cells migrated at a 
lower molecular weight than in the other two expression systems, possibly related to 
the degree of glycosylation.  Extensive glycosylation can be problematic for 
downstream structural biology, thus this was perceived as another benefit of the Sf9 
cell system.  Therefore the Sf9 expression system was taken forward to assess if the 
MRP4 expressed was functional.  
 
Vesicular Transport 
Finding the balance between overexpression and quality needs to be obtained. 
Therefore it is vital to ascertain that the protein is functional following 
overexpression. To facilitate this a fluorescent vesicular transport assay (VTA) was 
used.  cAMP is a known substrate for MRP425 and this assay utilises a fluorescent 
analogue of cAMP: 8- (2- [Fluoresceinyl]aminoethylthio)adenosine- 3', 5'- cyclic 
monophosphate (fluo-cAMP). This substrate had previously been reported to be 
transported by MRP4 within renal proximal tubules and by MRP4 overexpressed in 
Sf9 membrane vesicles23. By measuring the amount of substrate transported into the 
vesicle when ATP is present compared to AMP the specific transport activity can be 
determined (Figure 2).  
Figure 3A shows a significant increase in the transport of fluo-cAMP in the presence 
of ATP compared to AMP in Sf9 MRP4 vesicles, showing ATP dependent transport 
of fluo-cAMP. MRP4 was shown to be responsible for the transport of fluo-cAMP as 
there is an increase in ATP dependent specific activity of Sf9 MRP4 vesicles 
compared to Sf9 control vesicles (Figure 3B). There was a positive correlation of 
ATP dependent specific activity in Sf9 MRP4 vesicles with increased total membrane 
protein content, again indicating that MRP4 was responsible for the transport of fluo-
cAMP. Whereas the Sf9 control vesicles had a steady background fluorescence with 
increasing total membrane protein content. Figure 3C demonstrates a concentration 
dependent transport of fluo-cAMP with a Km of 5.8μM, which is comparable to 
previously reported values23. 
ATP hydrolysis is needed for the transport of substrates with MRP4 and inhibiting 
ATP hydrolysis should therefore inhibit transport. As shown in Figure 4A in the 
presence of vanadate or the non-hydrolysable ATP analogue AMP-PNP, the uptake 
is reduced to the same level as with AMP indicating that ATP is the driving force 
behind the transport of fluo-cAMP.  MK571, a known inhibitor of MRP4, was also 
used to demonstrate the functionality of MRP4. MK571 inhibits transport of 
substrates by binding within the transmembrane domains rather than the nucleotide 
binding sites like vanadate and AMP-PNP26. MK571 inhibits the transport of fluo-
cAMP in a concentration dependent manner with an IC50 of 0.39μM.  
These results verify that MRP4 expressed in Sf9 cells is functional as it is 
responsible for the transport of fluo-cAMP in a concentration and ATP dependent 
manner and was prevented by inhibiting either ATP hydrolysis or substrate binding. 
  
Discussion 
The need for good starting material is paramount in elucidating the function and 
structure of membrane proteins. To address this we investigated MRP4 expression 
in three different systems, Sf9 insect cells, P. pastoris yeast and HEK293T 
mammalian cells. All three of these systems have been successfully utilised in the 
past for overexpression of mammalian ABC transporters for functional and structural 
studies.  
P. pastoris has been successfully used for the overexpression of mouse 
MRP1/ABCC127, 28, mouse P-glycoprotein/ABCB129 and human TAP1/230. In this 
study we found that human MRP4 could also be successfully overexpressed using 
P. pastoris. Surprisingly, the level of expression achieved was lower when using a 
bioreactor rather than shaker flask cultures (Supplementary Figure 1B). With a 
bioreactor it is possible to continuously monitor and respond to the conditions within 
the culture such as oxygenation and pH, thus it might be considered to be more 
optimal for cell growth. Although we were able to grow the yeast to very high cell 
densities within the bioreactor, this didn’t translate into high expression levels of 
MRP4. Following optimisation of the shaker flask conditions the level of MRP4 
expression achieved was still lower than that obtained when using Sf9 insect cells 
(Figure 1B).  It might be that codon optimisation of the construct could help improve 
this further in the future31.  
The expression of MRP4 within Sf9 cells has been reported previously21, 23, 24, 32, 33, 
however this has predominantly been utilised for functional assays to date, rather 
than with the aim to develop an expression system for future purification. Here we 
showed that MRP4 with a his-affinity tag could be successfully overexpressed in Sf9 
cells, and the expression level could be optimised by changing the time of infection 
(Figure 1A).  Insect cells have previously been utilised for the expression, purification 
and structural study of human P-glycoprotein/ABCB134, although this used High Five 
(Trichoplusia ni) cells rather than Sf9 cells.  Insect cells have also been proven to be 
especially useful for structural studies on GPCRs (G-protein coupled receptors), 
which have shown a preference for Sf9 cells35.  
The overexpression of MRP4 in HEK cells has also been reported many times 
previously32, 36-38, but again to date this has mainly been for the purposes of 
functional studies. Transient transfection of HEK cells has been carried out using the 
transfection reagent Lipofectamine36. In this study we have successfully shown 
overexpression of MRP4 in HEK cells using the much cheaper reagent PEI 
(Supplementary Figure 1C). PEI has also been successfully utilised for the 
transfection of HEK cells with the related protein ABCG239. However interestingly 
this only worked successfully for the un-tagged MRP4 construct (Supplementary 
Figure 1C). For two different constructs containing MRP4 with a C-terminal his-tag, 
only minor, if any, overexpression was achieved (Figure 1C and Supplementary 
Figure 1C). It is unclear at this point if this could be improved with the use of an 
alternative transfection reagent. It is known that MRP4 contains a PDZ motif at its C-
terminal which is important for interaction with other proteins and localization within 
mammalian cells40 and perhaps the his-tag interferes in some way. An alternative 
approach to transfection, that has been successfully utilised for HEK expression of 
other ABC transporters for structural studies, is transduction of HEK cells with a 
recombinant baculovirus containing a mammalian promoter41, 42. 
Notably both the P. pastoris and HEK expressed MRP4 migrated at higher molecular 
weights than the Sf9 MRP4 (Figure 1B and 1C). It is known that MRP4 is 
glycosylated36 and Sf9 cells are only able to carry out simple mannose 
glycosylation6, so this difference is likely to be due to differential glycosylation in the 
three systems. Glycosylation can be problematic for structural studies since it adds 
heterogeneity.  
Taken together the higher yield of MRP4, potential lower levels of glycosylation and 
ease of scale up led us to choose Sf9 cell expression to proceed with.  
The next step was to check that the Sf9 overexpressed MRP4 was functional. 
Typically function is assessed by vesicular transport assays (VTAs) using 
radiolabelled substrates, however a fluorescent based assay can be both cheaper 
and easier. It was previously shown that MRP4 can transport the fluorescent 
analogue of cAMP, fluo-cAMP23. We found that crude membranes of Sf9 cells 
expressing MRP4 were able to transport fluorescent cAMP in an ATP dependent 
manner (Figure 3). The Km of fluo-cAMP was found to be very similar to that found in 
the previous study23 showing that this method is a robust way of determining the 
functionality of MRP4 using fluorescent analogues. Transport was also inhibited by 
MK571 and ATP analogues confirming its functionality (Figure 4). 
During this study, both a rapid filtration and centrifugation technique were tested for 
separating free fluo-cAMP from the vesicles (Figure 2). Rapid filtration is typically 
used with radiolabelled substrates, however with the fluorescent assay particles from 
the filters caused an increase in light scattering which decreased the signal to noise 
ratio. PVDF filters were better than glass fibre filters, however the centrifugation 
method improved this even further, as well as increasing the efficiency of the 
transport assay.  
In conclusion we have successfully demonstrated functional overexpression of 
MRP4 in Sf9 cells that can now be taken forward for solubilisation and purification to 
enable mechanistic and structural studies.  
Figure Legends 
Figure 1: Overexpression trials for MRP4 in Sf9 insect cells, P. pastoris yeast 
cells and HEK293T mammalian cells. A; Western blot of MRP4 in Sf9 insect cell 
membranes after 48 and 72 hours using an MOI of 2 or 4 with 1 or 2 x 106 Sf9 
cells/mL. 5μg of total protein was loaded for each condition. +ve represents a control 
sample of MRP4 expressed in Sf9 cells which was quantified, aliquoted and frozen 
to be used as a control/standard on all Western blots to allow reliable comparison 
across different experiments. B; membrane expression levels in P. pastoris yeast 
cells after 24, 48 and 72 hours at 22oC and 30oC. 5 or 20μg of total protein was 
loaded, and compared to the Sf9 control expression levels (Sf9, 5µg total protein). C; 
Expression of MRP4 in HEK293T cell after 24, 48 and 72 hours. Controls include 
untreated HEK293T cells (-ve), treatment with PEI only or with an empty pcDNA3.1 
vector (VC), and the Sf9 control expression sample (Sf9). Each HEK sample 
contained 20µg total protein, whereas the Sf9 control contained 10µg. A & B were 
probed with an anti-his primary antibody and an anti-mouse HRP secondary 
antibody. C was probed with an anti-MRP4 primary antibody and an anti-rat HRP 
secondary antibody.  
Figure 2: Schematic of the steps in the vesicular transport assay. The first step 
is the incubation of the fluorescent cAMP substrate (green stars) with the membrane 
vesicles (orange circles) in the presence of AMP or ATP (along with an ATP 
regenerating system). The fluorescent cAMP is transported into the membrane 
vesicles via ATP hydrolysis. The vesicles are then either filtered or centrifuged to 
remove all excess fluo-cAMP. The vesicles are then solubilised and the amount of 
fluorescent cAMP transported into the vesicles is measure on a fluorescent 
spectrometer. The difference between ATP and AMP is calculated giving the specific 
transport activity. 
Figure 3: Vesicular uptake of fluo-cAMP is both ATP and MRP4 dependent. A; 
The relative fluorescence of membrane vesicles containing MRP4 when incubated 
with fluo-cAMP in the presence of ATP or AMP. 20μg of total membrane protein, with 
a 10 minute incubation period and 10μM fluo-cAMP. Data are mean ± SEM (n=3) 
Un-paired two-tailed t-test **** P<0.001. B;  Specific transport activity of Sf9 control 
vesicles (Sf9) and Sf9 vesicles overexpressing MRP4 (Sf9 MRP4) using 10 -100μg 
total membrane proteins and 10μM fluo-cAMP, with a 10min incubation time. Data 
are mean ± SEM (n=3) Two-way ANOVA** P=0.01 ****P<0.001. C; Specific transport 
activity of Sf9 MRP4 membrane vesicles (50µg protein) using 0 – 50 μM fluo-cAMP 
showing a concentration dependent increase. Data are mean ± SEM, n≥2, Vmax 64 
RFU, Km 5.8 μM, Michaelis-Menten curve fitted. 
Figure 4: Vesicular uptake of fluo-cAMP is inhibited by non-hydrolysable ATP 
analogues and MK571. A; fluo-cAMP transported (RFU) in the presence of ATP 
(10mM), AMP (10mM), ATP (10mM) plus vanadate (500 µM) (ATP + V) or the non-
hydrolysable ATP analogue AMP-PNP (10 mM). 30μg total membrane protein (Sf9 
MRP4) with an incubation period of 10 minutes and 10μM fluo-cAMP. Data are mean 
± SEM (n=3), 1 way ANOVA, multiple comparisons**** P<0.001. B; Dose dependent 
inhibition of fluo-cAMP (10µM) transport by MRP4 Sf9 membrane vesicles (50µg 
protein) in the presence of 0.01 - 5μM MK571, with a 10 minute incubation time. The 
percent of ATP specific transport was measured using ATP as 100%. Data are mean 
± SEM, n=3, IC50=0.39μM MK571, [inhibitor] vs normalised response curve fitted.  
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Supplementary Figure 1: Overexpression trials for MRP4 in Sf9 insect cells, P. 
pastoris yeast cells and HEK293T mammalian cells. A; Western blot of MRP4 in Sf9 
insect cells (whole cell lysates) after 24 and 48 hours using an MOI of 2 or 4 with 1 or 2 x 106 
Sf 9 cells/mL. +ve represents a control/standard sample of MRP4. B; membrane expression 
levels in P. pastoris yeast cells grown in a 2L bioreactor in comparison to P. Pastoris grown 
in shaker flasks. Specified amounts (μg) of total protein were loaded, and compared to 
control Sf9 expression levels (Sf9, 3µg total protein). C; Expression of MRP4 in HEK293T 
cells after 24, 48 and 72 hours using the pcDNA3.1-MRP4 un-tagged construct or the 
pOPINE-MRP4-3C-flag-his8 construct. Controls include untreated HEK293T cells (-ve), 
treatment with PEI only or with an empty pcDNA3.1 vector (VC) and an Sf9 expressed 
MRP4 positive control (10µg). All HEK samples contain 20µg total protein. A & B were 
probed with an anti-his primary antibody and an anti-mouse HRP secondary antibody. C was 
probed with an anti-MRP4 primary antibody and an anti-rat HRP secondary antibody.  
